Lithium Ion

Lithium Ion

SCHEMBL1504034

CN(C(=O)OC(C)(C)C)C1CCc2nc(C(=O)[O-])sc2C1.[Li+]

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.34
DRD3 P35462 2/20 0.34
HSD11B1 P28845 1/20 0.34
SCN4A P35499 1/20 0.33
SCN5A Q14524 1/20 0.32
SCN3A Q9NY46 1/20 0.32
PDK1 Q15118 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SPR P35270 1/20 0.31
TP53 P04637 3/20 0.30
MAPT P10636 2/20 0.30
RXFP1 Q9HBX9 1/20 0.30
POLB P06746 1/20 0.30
PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504035 0.87 DRD2 (0.34) DRD2DRD3HSD11B1SCN4ASCN5A
SCHEMBL29840403 0.83 DRD2 (0.36) DRD2DRD3HSD11B1SCN4ASCN5A
Lithium Ion SCHEMBL1503758 0.83 DRD2 (0.39) DRD2DRD3PDK1NPC1RAB9A
SCHEMBL3310859 0.82 DRD2 (0.36) DRD2DRD3HSD11B1SCN4ASCN5A
SCHEMBL31564195 0.71 HSD11B1 (0.35) HSD11B1SMN1; SMN2SPRMAPT
SCHEMBL31564325 0.71 HSD11B1 (0.35) HSD11B1SMN1; SMN2SPRMAPT
SCHEMBL12035209 0.70 DRD2 (0.41) DRD2DRD3PDK1NPC1RAB9A
SCHEMBL31564060 0.69 HSD11B1 (0.34) HSD11B1SMN1; SMN2SPRMAPT
SCHEMBL31564466 0.69 ADORA2A (0.35) DRD2DRD3HSD11B1SPR
SCHEMBL31564374 0.69 HSD11B1 (0.34) DRD2DRD3HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1405852-B9 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-03-27 EP disclosed
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP disclosed
EP-1405852-B1 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2012-08-01 EP disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed
US-20100093785-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-15 US disclosed
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM DAIICHI PHARMACEUTICAL CO., LTD (JP) 2009-11-12 US disclosed
US-20090270446-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-10-29 US disclosed
US-7576135-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-08-18 US disclosed
US-7365205-B2 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-04-29 US disclosed
US-7342014-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-11 US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 US disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270446-A1 DIAMINE DERIVATIVES F2, TFPI, F3 DRD2 1376/4885DRD3 1671/4885HSD11B1 4590/4885
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES F2, PLAT, MPL DRD2 1524/4885DRD3 1542/4885HSD11B1 1142/4885
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 DRD2 962/4885DRD3 741/4885HSD11B1 2197/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R DRD2 351/4885DRD3 353/4885HSD11B1 2283/4885
US-20080015215-A1 DIAMINE DERIVATIVES C9, C1S, C1R DRD2 351/4885DRD3 353/4885HSD11B1 2283/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R DRD2 351/4885DRD3 353/4885HSD11B1 2283/4885
US-20100093785-A1 DIAMINE DERIVATIVES C9, C1S, C1R DRD2 229/4885DRD3 218/4885HSD11B1 2184/4885
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM C1R, C9, F2 DRD2 352/4885DRD3 336/4885HSD11B1 3154/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R DRD2 351/4885DRD3 353/4885HSD11B1 2283/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 DRD2 1376/4885DRD3 1671/4885HSD11B1 4590/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R DRD2 352/4885DRD3 318/4885HSD11B1 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.